Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Horizon, Redx to advance pan-RAF inhibitors
October 2015
SHARING OPTIONS:

CAMBRIDGE, U.K.—A research collaboration was recently announced between Horizon Discovery Group plc and Redx Pharma plc focused on progressing Redx’s novel pan-RAF inhibitor program for out-licensing in oncology indications, including colorectal cancer. Horizon will use its proprietary gene editing, cell line and drug discovery technology platforms to explore the mode of action for the inhibitors and support Redx in its efforts to move the compounds toward partnering. Though no financial details were disclosed, Horizon and Redx will bear collaboration costs proportionate to their respective research activities. Should a program asset be partnered with a pharmaceutical company, it is expected to deliver a material return on Horizon’s investment from any upfront payment, a share of future milestones and a share of future product royalties.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.